Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass. June 24, 2024 - Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company, has announced new preclinical data that showcase the potential of their FORCE platform to deliver enzyme replacement therapy (ERT) to cardiac and skeletal muscles as well as the central nervous system (CNS) in Pompe disease. The data was presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, which took place from June 23-26 in Fort Lauderdale, FL.
Pompe disease is a rare and progressive muscular disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA) that leads to the accumulation of glycogen in the muscles and tissues. Currently, there is no cure for Pompe disease, and the available treatment options, including ERT, have shown limited benefit. Dyne Therapeutics aims to address this unmet medical need by developing a novel therapeutic approach using their proprietary FORCE platform.
The FORCE platform is a cutting-edge technology that utilizes the company’s proprietary muscle-targeting peptide conjugates (MTPCs) and other advanced delivery mechanisms to transport therapeutic molecules to targeted tissues. By harnessing the power of natural cellular transport pathways, the FORCE platform has the potential to effectively deliver ERT to cardiac and skeletal muscles, as well as the CNS, in patients with Pompe disease.
The preclinical data presented by Dyne Therapeutics demonstrated the successful delivery of enzyme replacement therapy to key tissues affected by Pompe disease in animal models. The results showed a significant reduction in glycogen accumulation in both cardiac and skeletal muscles, as well as improvement in cognitive function and motor performance associated with CNS involvement.
These findings highlight the promise of the FORCE platform in addressing the limitations of current treatment options for Pompe disease. By enabling the efficient and targeted delivery of ERT, Dyne Therapeutics’ innovative approach has the potential to improve clinical outcomes and transform the lives of patients living with this debilitating condition.
In addition to the recent preclinical data, Dyne Therapeutics has previously announced compelling results from their ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD. In the Phase 1/2 ACHIEVE Trial, DYNE-101 demonstrated a dose-dependent 27% mean splicing correction across all patients in the 5.4 mg/kg cohort at 3 months. These findings suggest the broad therapeutic potential of Dyne Therapeutics’ technology in various genetic diseases.
To share the latest clinical data from their ACHIEVE and DELIVER trials, Dyne Therapeutics will be hosting a virtual investor event on May 20, 2024, at 8:00 a.m. ET. The event aims to provide a comprehensive review of the new efficacy and safety data, highlighting the significant impact on key disease biomarkers and improvement in multiple functional endpoints.
The updated release of clinical trial data signifies Dyne Therapeutics’ commitment to advancing innovative therapies for genetically driven diseases. The company’s dedication to delivering safe and effective treatments offers hope to patients and their families. With ongoing advancements in the FORCE platform and promising preclinical and clinical data, Dyne Therapeutics is well on its way to revolutionizing the treatment landscape for Pompe disease and other genetic disorders.
Comments